MX2023000099A - Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes. - Google Patents
Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes.Info
- Publication number
- MX2023000099A MX2023000099A MX2023000099A MX2023000099A MX2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A MX 2023000099 A MX2023000099 A MX 2023000099A
- Authority
- MX
- Mexico
- Prior art keywords
- glucokinase
- treating diabetes
- nucleic acids
- modified insulin
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01002—Glucokinase (2.7.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047965P | 2020-07-03 | 2020-07-03 | |
| US202063054162P | 2020-07-20 | 2020-07-20 | |
| US202063067264P | 2020-08-18 | 2020-08-18 | |
| US202163141918P | 2021-01-26 | 2021-01-26 | |
| US202163188778P | 2021-05-14 | 2021-05-14 | |
| PCT/US2021/040366 WO2022006551A2 (en) | 2020-07-03 | 2021-07-02 | Modified insulin and glucokinase nucleic acids for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000099A true MX2023000099A (es) | 2023-04-20 |
Family
ID=79317842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000099A MX2023000099A (es) | 2020-07-03 | 2021-07-02 | Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240279300A1 (https=) |
| EP (1) | EP4176060A4 (https=) |
| JP (2) | JP7837963B2 (https=) |
| KR (1) | KR20230087436A (https=) |
| CN (1) | CN116234904A (https=) |
| AU (1) | AU2021300450A1 (https=) |
| CA (1) | CA3174156A1 (https=) |
| IL (1) | IL299545A (https=) |
| MX (1) | MX2023000099A (https=) |
| WO (1) | WO2022006551A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023259404A1 (en) * | 2022-04-29 | 2024-11-28 | Kriya Therapeutics, Inc. | Insulin and glucokinase gene therapy compositions and its use for treating diabetes |
| AU2024370040A1 (en) * | 2023-11-01 | 2026-04-23 | Kriya Therapeutics, Inc. | Aav mediated insulin and glucokinase gene therapy for treating diabetes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633876T3 (pl) * | 2003-06-17 | 2009-01-30 | Sembiosys Genetics Inc | Sposoby wytwarzania insuliny w roślinach |
| EP2605798A1 (en) * | 2010-07-12 | 2013-06-26 | Universidad Autònoma de Barcelona | Gene therapy composition for use in diabetes treatment |
| US11033638B2 (en) * | 2015-01-07 | 2021-06-15 | Universität Autonoma De Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
-
2021
- 2021-07-02 EP EP21833939.8A patent/EP4176060A4/en active Pending
- 2021-07-02 AU AU2021300450A patent/AU2021300450A1/en active Pending
- 2021-07-02 KR KR1020237003717A patent/KR20230087436A/ko active Pending
- 2021-07-02 MX MX2023000099A patent/MX2023000099A/es unknown
- 2021-07-02 IL IL299545A patent/IL299545A/en unknown
- 2021-07-02 US US18/003,980 patent/US20240279300A1/en active Pending
- 2021-07-02 CA CA3174156A patent/CA3174156A1/en active Pending
- 2021-07-02 JP JP2023524498A patent/JP7837963B2/ja active Active
- 2021-07-02 CN CN202180052115.3A patent/CN116234904A/zh active Pending
- 2021-07-02 WO PCT/US2021/040366 patent/WO2022006551A2/en not_active Ceased
-
2025
- 2025-12-16 JP JP2025256145A patent/JP2026034616A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3174156A1 (en) | 2022-01-06 |
| EP4176060A2 (en) | 2023-05-10 |
| JP2026034616A (ja) | 2026-02-27 |
| WO2022006551A2 (en) | 2022-01-06 |
| JP7837963B2 (ja) | 2026-03-31 |
| AU2021300450A1 (en) | 2023-03-02 |
| EP4176060A4 (en) | 2024-08-07 |
| JP2023542241A (ja) | 2023-10-05 |
| KR20230087436A (ko) | 2023-06-16 |
| US20240279300A1 (en) | 2024-08-22 |
| CN116234904A (zh) | 2023-06-06 |
| WO2022006551A3 (en) | 2022-02-03 |
| IL299545A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000099A (es) | Acidos nucleicos de insulina y glucocinasa modificados para el tratamiento de la diabetes. | |
| MX2022005236A (es) | Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina. | |
| MX2015014464A (es) | Vectores para terapia genica para tratar cardiomiopatía. | |
| PH12020550766A1 (en) | Synp61, a primate retinal pigment epithelium cell-specific promoter | |
| NZ718173A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| WO2022046935A3 (en) | Methods and compositions for treating glioblastoma | |
| MX2020005324A (es) | Microorganismo modificado geneticamente para producir acido 3-hidroxidadipico, acido alfa-hidromuconico y/o acido adipico, y metodo de produccion para tales productos quimicos. | |
| AR105822A1 (es) | Análogos de insulina | |
| MX2021003261A (es) | Neurotoxinas clostridiales que comprenden un bucle de activacion exogeno. | |
| CR20200210A (es) | Promotor especìfico de las cèlulas del epitelio pigmentario retinal en primates | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| WO2020163743A8 (en) | Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems | |
| MX2021003567A (es) | Métodos y composiciones para aumentar la expresión de proteínas y/o tratar un trastorno por haploinsuficiencia. | |
| PH12019502522A1 (en) | Oncolytic virus and method | |
| MX2023011035A (es) | Composición de terapia génica y tratamiento de la miocardiopatía arritmogénica del ventriculo derecho. | |
| MX2016012558A (es) | Suministro sistemico de vectores de virus que codifican urocortina-2 y genes relacionados para tratar disfunciones cardiacas relacionadas con diabetes y falla de corazon congestivo. | |
| EA201170917A1 (ru) | Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней | |
| PH12020551191A1 (en) | Oligodendrocyte-specific promoter, mirna specific to plp1 gene, vector including said promoter and/or mirna, and pharmaceutical composition including said vector | |
| MX2025009545A (es) | Metodos y composiciones para la administracion de sistemas de vector dual otoferlin | |
| ZA202304029B (en) | Cxcl9 and variants thereof for immunotherapy of cancer diseases | |
| MY170467A (en) | High molecular weight pha-producing microbe and method of producing high molecular weight pha using same | |
| PH12017502323B1 (en) | Novel xylanase | |
| MY182443A (en) | Method of producing lipid | |
| IN2014DE00902A (https=) | ||
| MY200951A (en) | Variants Of Porcine Trypsin |